Germline polymorphisms in an enhancer of <i>PSIP1</i> are associated with progression-free survival in epithelial ovarian cancer
Juliet D. French(The University of Queensland), Allan Jensen(Danish Cancer Society), Yukie T. Bean(Oregon Health & Science University), Yi Lu(Karolinska Institutet), Michelle J. Henderson(New South Wales Department of Health), Peter A. Fasching(Universitätsklinikum Erlangen), Sharon E. Johnatty(QIMR Berghofer Medical Research Institute), Florian Heitz(Kliniken Essen-Mitte), Murugan Kalimutho(Griffith University), Estrid Høgdall(University of Copenhagen), Susanne K. Kjær(Copenhagen University Hospital), Marc T. Goodman(Cedars-Sinai Medical Center), Matthias W. Beckmann(Universitätsklinikum Erlangen), Arif B. Ekici(University Medical Center Groningen), Andreas du Bois(Kliniken Essen-Mitte), Darren Korbie(The University of Queensland), Amanda J. Russell(University of Minnesota), Ignace Vergote(KU Leuven), Evelyn Despierre(KU Leuven), Yasushi Yatabe(University Hospital Münster), Keitaro Matsuo(Aichi Cancer Center), Tanja Pejović(Oregon Health & Science University), Christine M. Walsh(University of Calgary), Toru Nakanishi(Tohoku Medical and Pharmaceutical University Hospital), Bo Gao(Sun Yat-sen University), Susanne Kaufmann(QIMR Berghofer Medical Research Institute), Siddhartha Kar(University of Cambridge), Sandra Oršulić(Cedars-Sinai Medical Center), Philipp Harter(Kliniken Essen-Mitte), Diether Lambrechts(VIB-KU Leuven Center for Cancer Biology), Satoyo Hosono(Aichi Cancer Center), Beth Y. Karlan(University of California, Los Angeles), Els Van Nieuwenhuysen, Alexander Hein, Ira Schwaab(Cancer Institute of New South Wales), Jacobus Pisterer(Aichi Cancer Center), Chen Wang(Xiamen University), Galina Lurie(Cancer Prevention Institute of California), Haran Sivakumaran(QIMR Berghofer Medical Research Institute), Jonathan Beesley(QIMR Berghofer Medical Research Institute), Rayna K. Matsuno(Cancer Prevention Institute of California), Jenny Lester(Cedars-Sinai Medical Center), Sandrina Lambrechts(Dartmouth College), Pamela J. Thompson(Cancer Prevention Institute of California), Peter Hillemanns(Medizinische Hochschule Hannover), Kristine M. Hillman(The University of Queensland), Martin O’Reilly(Cancer Research UK)
Cited by 36
Related Papers
Integrated genomic analyses of ovarian carcinoma
|Nature|2011|8.2k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k